Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 33 studies | 37% ± 19% | |
macrophage | 16 studies | 33% ± 15% | |
microglial cell | 15 studies | 62% ± 20% | |
mesothelial cell | 13 studies | 63% ± 23% | |
type II pneumocyte | 11 studies | 49% ± 19% | |
club cell | 11 studies | 31% ± 12% | |
epithelial cell | 8 studies | 27% ± 9% | |
secretory cell | 8 studies | 37% ± 11% | |
basal cell | 6 studies | 22% ± 8% | |
respiratory goblet cell | 6 studies | 47% ± 18% | |
connective tissue cell | 6 studies | 34% ± 16% | |
hepatocyte | 6 studies | 89% ± 7% | |
T cell | 5 studies | 25% ± 5% | |
adventitial cell | 5 studies | 75% ± 10% | |
deuterosomal cell | 4 studies | 26% ± 7% | |
astrocyte | 4 studies | 25% ± 6% | |
ciliated cell | 4 studies | 26% ± 7% | |
myeloid cell | 4 studies | 36% ± 17% | |
duct epithelial cell | 3 studies | 67% ± 13% | |
cholangiocyte | 3 studies | 69% ± 27% | |
endothelial cell of sinusoid | 3 studies | 30% ± 14% | |
hepatic stellate cell | 3 studies | 52% ± 22% | |
abnormal cell | 3 studies | 36% ± 18% | |
conventional dendritic cell | 3 studies | 37% ± 3% | |
endothelial cell | 3 studies | 47% ± 24% | |
pancreatic ductal cell | 3 studies | 50% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 414452.27 | 226 / 226 | 99% | 3352.33 | 402 / 406 |
lung | 98% | 51816.03 | 567 / 578 | 74% | 316.46 | 854 / 1155 |
breast | 99% | 63197.63 | 453 / 459 | 72% | 216.83 | 806 / 1118 |
ovary | 79% | 62248.03 | 142 / 180 | 86% | 718.07 | 371 / 430 |
pancreas | 69% | 31594.15 | 226 / 328 | 86% | 534.43 | 153 / 178 |
thymus | 87% | 28222.85 | 567 / 653 | 56% | 187.05 | 337 / 605 |
bladder | 95% | 59012.52 | 20 / 21 | 37% | 104.20 | 186 / 504 |
kidney | 46% | 14018.10 | 41 / 89 | 81% | 657.61 | 731 / 901 |
esophagus | 84% | 39533.45 | 1220 / 1445 | 42% | 155.10 | 76 / 183 |
intestine | 87% | 36553.79 | 840 / 966 | 31% | 116.91 | 165 / 527 |
adrenal gland | 99% | 82963.43 | 255 / 258 | 19% | 115.33 | 44 / 230 |
uterus | 74% | 28708.39 | 125 / 170 | 35% | 144.19 | 159 / 459 |
stomach | 55% | 26379.66 | 199 / 359 | 50% | 190.20 | 142 / 286 |
adipose | 100% | 106689.39 | 1200 / 1204 | 0% | 0 | 0 / 0 |
brain | 19% | 3368.57 | 489 / 2642 | 72% | 299.22 | 509 / 705 |
skin | 59% | 14983.04 | 1074 / 1809 | 27% | 58.03 | 129 / 472 |
heart | 82% | 29577.02 | 703 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 80% | 30951.09 | 1070 / 1335 | 0% | 0 | 0 / 0 |
prostate | 42% | 9590.88 | 104 / 245 | 21% | 38.15 | 106 / 502 |
lymph node | 0% | 0 | 0 / 0 | 62% | 121.43 | 18 / 29 |
tonsil | 0% | 0 | 0 / 0 | 40% | 76.98 | 18 / 45 |
muscle | 17% | 2471.96 | 135 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 7.10 | 3 / 80 |
peripheral blood | 1% | 189.37 | 10 / 929 | 0% | 0 | 0 / 0 |
spleen | 1% | 883.83 | 2 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006957 | Biological process | complement activation, alternative pathway |
GO_0006954 | Biological process | inflammatory response |
GO_0010828 | Biological process | positive regulation of glucose transmembrane transport |
GO_0016322 | Biological process | neuron remodeling |
GO_0150062 | Biological process | complement-mediated synapse pruning |
GO_0097278 | Biological process | complement-dependent cytotoxicity |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0009617 | Biological process | response to bacterium |
GO_0007165 | Biological process | signal transduction |
GO_0150064 | Biological process | vertebrate eye-specific patterning |
GO_0001934 | Biological process | positive regulation of protein phosphorylation |
GO_0006956 | Biological process | complement activation |
GO_0006631 | Biological process | fatty acid metabolic process |
GO_0035846 | Biological process | oviduct epithelium development |
GO_0045745 | Biological process | positive regulation of G protein-coupled receptor signaling pathway |
GO_0097242 | Biological process | amyloid-beta clearance |
GO_0048260 | Biological process | positive regulation of receptor-mediated endocytosis |
GO_0006955 | Biological process | immune response |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0001970 | Biological process | positive regulation of activation of membrane attack complex |
GO_0006958 | Biological process | complement activation, classical pathway |
GO_2000427 | Biological process | positive regulation of apoptotic cell clearance |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0060100 | Biological process | positive regulation of phagocytosis, engulfment |
GO_0010884 | Biological process | positive regulation of lipid storage |
GO_0010866 | Biological process | regulation of triglyceride biosynthetic process |
GO_0001798 | Biological process | positive regulation of type IIa hypersensitivity |
GO_0002430 | Biological process | complement receptor mediated signaling pathway |
GO_0035578 | Cellular component | azurophil granule lumen |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0034774 | Cellular component | secretory granule lumen |
GO_0072562 | Cellular component | blood microparticle |
GO_0009986 | Cellular component | cell surface |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0004866 | Molecular function | endopeptidase inhibitor activity |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0031715 | Molecular function | C5L2 anaphylatoxin chemotactic receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | C3 |
Protein name | Complement C3 (C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1) [Cleaved into: Complement C3 beta chain; C3-beta-c (C3bc); Complement C3 alpha chain; C3a anaphylatoxin; Acylation stimulating protein (ASP) (C3adesArg); Complement C3b alpha' chain; Complement C3c alpha' chain fragment 1; Complement C3dg fragment; Complement C3g fragment; Complement C3d fragment; Complement C3f fragment; Complement C3c alpha' chain fragment 2] Complement C3 |
Synonyms | CPAMD1 |
Description | FUNCTION: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.; FUNCTION: Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. In chronic inflammation, acts as a chemoattractant for neutrophils (By similarity). It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. .; FUNCTION: [C3-beta-c]: Acts as a chemoattractant for neutrophils in chronic inflammation. .; FUNCTION: [Acylation stimulating protein]: Adipogenic hormone that stimulates triglyceride (TG) synthesis and glucose transport in adipocytes, regulating fat storage and playing a role in postprandial TG clearance. Appears to stimulate TG synthesis via activation of the PLC, MAPK and AKT signaling pathways. Ligand for C5AR2. Promotes the phosphorylation, ARRB2-mediated internalization and recycling of C5AR2 . . FUNCTION: Acts as a chemoattractant for neutrophils in chronic inflammation. .; FUNCTION: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. . FUNCTION: Acts as a chemoattractant for neutrophils in chronic inflammation. .; FUNCTION: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. . |
Accessions | ENST00000695655.1 M0QXZ3 M0QYC8 ENST00000596548.1 A0A8Q3WM02 M0R1Q1 A0A8Q3SI34 P01024 A0A8Q3SI22 ENST00000602229.1 ENST00000245907.11 ENST00000695654.1 A0A8Q3SI05 ENST00000695653.1 A0A8Q3SI45 ENST00000695652.1 A0A8Q3WLS3 ENST00000594270.5 ENST00000600744.1 ENST00000695693.1 ENST00000601008.1 A0A8Q3WKN7 M0R0Q9 ENST00000695689.1 |